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Summary
Serological methods for antiplatelet antibody determination have contributed to the under-
standing and better diagnosis of immune mediated thrombocytopenia. Although most tests for 
determination of antiplatelet antibodies were initially introduced for antibody detection in pati-
ents with idiopathic thrombocytopenic purpura, nowadays these methods are used in the dia-
gnosis of platelet disorders when an immune pathomechanism is suspected. Serological testing 
is mostly used in the diagnosis of foetal and neonatal alloimmune thrombocytopenia, post-tran-
sfusion thrombocytopenic purpura and platelet transfusion refractoriness and of primary and se-
condary autoimmune thrombocytopenia. Development of molecular biology has enabled more 
accurate determination of platelet antigens and assessment of their prevalence in the population. 
These advancements have upgraded evaluation of the role of particular antigen systems in the 
etiology of auto- and alloimmune thrombocytopenic syndromes, association of human platelet 
antigen polymorphisms with susceptibility to cardiac and cerebrovascular diseases, and outcome 
of allogeneic bone marrow and solid organ transplantation.
Key words: human platelet antigens (HPA), antiplatelet auto- and alloantibodies, anti-HLA-I 
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INTRODUCTION
Platelet antigens and respective antiplatelet antibodies play a major role in the 
immune mediated platelet disorders. As early as the 1950s, clinical observations 
suggested the existence of antiplatelet antibodies. The first platelet antigen Zwa or 
P1A1 was discovered by Longhem in 1959, and then independently by Shulman et 
al. in 1960 in a patient with thrombocytopenia of unknown cause [1].
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Platelet antigens
Platelet antigens are an integral part of the platelet membrane glycoprotein com-
plexes (GP IIb/IIIa, Ib/IX, Ia/IIa and Ic/IIa). The GP IIb/IIIa, GP Ic/IIa and GP Ia/IIa com-
plexes belong to the large group of cytoadhesive proteins known as integrins; besides 
platelets, they are also found on leukocytes, endothelial cells and fibroblasts. Specific 
platelet antigens and antigens common to blood cells and other tissues, human leuko-
cyte antigens class I (HLA-I), ABH, Le, I and P are expressed on the platelet membrane 
[2]. Specific human platelet antigens (HPA) have been traditionally defined as antigens 
found exclusively on circulating platelets and megakaryocytes. However, nowadays it 
is evident that most of these antigens are widely distributed in tissues and are found 
on the receptor molecules of the cell matrix and other cells. So, antigens located on the 
beta 3 integrin subunit have also been demonstrated on endothelial cells, fibroblasts 
and smooth muscle cells, while antigens located on the beta 2 integrin subunit are also 
expressed on the long-activated T lymphocytes and endothelial cells. In contrast, HPA-
2 and HPA-3 antigens expressed on GP IIb and GP Ib have only been demonstrated 
on platelets [3]. Antigen systems have been named with numbers from 1 onward, in 
the order of their detection. The alleles within the system are denoted by letters, where 
"a" denotes high frequency allele and "b" low frequency allele. HPA polymorphism is 
usually a result of single nucleotide exchange, which leads to one amino acid exchange 
in the platelet membrane protein. This exchange causes alteration in the tertiary struc-
ture and formation of immunogenic epitopes. All known platelet specific antigens are 
inherited as an autosomal codominant trait. The frequency of particular genotypes/
phenotypes varies greatly depending on the population and race [4].
Platelet HLA antigens are exclusively of class I, mostly A and B. HLA C antigens 
are very weakly expressed on platelet membrane. HLA-I expression varies conside-
rably depending on the antigen and the individual. Until recently, it was generally 
considered that HLA D and DR antigens were not expressed on platelet membrane; 
however, the latest researches suggest that the occurrence of HLA DR antigen can 
be induced by cytokines (e.g., gamma interferon). ABH antigens, located on glyco-
protein IIa and IIb, are in part integral membrane antigens and in part are adsorbed 
from plasma. Considering other antigens shared between platelets and red blood 
cells, Le antigens are adsorbed from plasma, whereas for example Rh antigens and 
other protein antigens have not been detected on platelet membrane [5].
Antiplatelet antibodies
Antiplatelet antibodies include autoantibodies, alloantibodies and isoantibo-
dies. Autoantibodies are directed against particular glycoprotein complexes of the 
Rad 524. Medical Sciences, 42 (2015) : 91-97
I. Jukić, M. Tomičić: Clinical relevance of antiplatelet antibodies
93
own platelet membrane. Alloantibodies are formed by immunization to foreign 
platelet alloantigens during blood and blood product transfusion, pregnancy and 
transplantation. Isoantibodies are formed when the platelet membrane lacks a par-
ticular glycoprotein complex [6].
Laboratory testing for antiplatelet antibodies
The methods of antiplatelet antibody determination can be divided into three 
groups according to the order of their widespread application in practice. First gro-
up includes the methods based on platelet function modification as a consequence 
of antiplatelet antibody binding to platelet antigens (thromboagglutination test, pla-
telet granule H3-serotonin release assay, cytoplasmic Cr51 release assay and platelet 
factor 3 assay). These first group assays are rarely used due to their low sensitivity 
and specificity. Second group assays (immunofluorescence assay, radioimmunopre-
cipitation assay and mixed hemagglutination assay) are based on the antiglobulin 
assay and are used to measure IgG and/or complement complexes on platelet mem-
branes. These assays can be direct or indirect. Direct assays measure IgG bound to 
patient platelets in vivo, whereas indirect assays determine the presence of free an-
tibodies in patient serum. Direct assay is known as platelet associated IgG (PAIgG). 
The least amount of IgG (surface and intracellular) identifiable by these assays is 10-
20 000 IgG molecules/platelet. Third group methods are employed to determine the 
presence and specificity of antiplatelet antibodies by use of monoclonal antibodies 
specific for the platelet glycoprotein complexes. The monoclonal antibody immobi-
lisation of platelet antigens (MAIPA) assay is the superior third group method [1,5].
Clinical relevance of antiplatelet antibodies and platelet antigens
Direct second and third group assays (PAIgG) are most frequently employed in 
the serological diagnosis of immune thrombocytopenia (ITP). The validity of the 
assays used for determination of antiplatelet autoantibodies on platelets and/or in 
serum of patients with ITP remains questionable in spite of the improved method 
specificity and sensitivity. Problems arise on result interpretation because platelets 
of both healthy individuals and patients with immune mediated or non-immune 
mediated thrombocytopenia can be lined with IgG molecules. These assays are not 
mandatory in setting the diagnosis of ITP but are supplementary to other clinical-
laboratory findings [7,8]. The diagnosis of foetal and neonatal alloimmune throm-
bocytopenia (FNAITP) is based on determination of antiplatelet antibody specificity 
in maternal, paternal and neonatal sera. This is accomplished by use of MAIPA and 
other third group assays. Maternal and paternal platelet cross-matching is useful in 
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detecting new antigen systems and alloantibodies to very high and low frequency 
antigens in the population. About 80%-90% of FNAITP cases are caused by anti-
HPA-1a antibodies. Anti-HPA-5b antibodies are the second most frequent antibodi-
es (15%), while other specific antibodies are rarely found [9, 10]. Finding compatible 
platelets for polytransfused patients alloimmunized to platelet antigens and refrac-
tory to platelet transfusion poses great problem to transfusion service. Refractori-
ness to platelet transfusion is observed in about half of the polytransfused patients. 
Although generally multifactorial, it frequently occurs consequentially to antibody 
activity. Over years, a number of methods of pretransfusion selection of platelet 
products have been introduced to enhance the effect of platelet transfusion [11,12]. 
Platelet transfusion with products prepared from HLA compatible donors, with or 
without previous cross-matching by the microlymphocytotoxicity test (MLCT), is 
most commonly used. The expected platelet count increase failed to occur in 20%-
30% of patients in spite of full platelet donor and recipient HLA compatibility and 
negative MLCT cross-match. The concurrence of specific antiplatelet antibodies that 
cannot be detected by the MLCT test has been postulated in these patients. Further-
more, the variable HLA antigen expression on platelets relative to lymphocytes used 
in the MLCT test was the reason to turn to the use of immunofluorescence assay, 
enzyme-immune assay (EIA) and erythrocyte adherence assay on cross-matching 
prior to platelet transfusion. Platelet product selection by cross-matching before pla-
telet transfusion yields satisfactory results of transfusion treatment in the majority 
of refractory alloimmunized patients. There is no generally adopted, standard cro-
ss-matching method, such as antiglobulin test in red cell serology [13]. Recently, the 
methods of molecular biology have been increasingly employed for platelet antigen 
determination. Molecular methods have enabled determination of polymorphisms 
and HPA allele frequency. Platelet glycoprotein polymorphism occurs due to mu-
tation of a particular gene sequence and is the cause of hereditary thrombocytope-
nia [14]. The GP IIb/IIIa gene mutations cause Glanzmann thrombasthenia, while 
GP Ib/IX/V gene mutations cause various forms of Bernard-Soulier syndrome and 
thrombocytic form of pseudo von Willebrand's disease. Epidemiological studies 
have revealed considerable ethnic differences in the frequency of particular HPA 
alleles, which can prove useful on estimating the likelihood of alloimmunization to 
particular HPA antigens and alloimmune thrombocytopenic syndromes. Determi-
nation of the HPA system alleles in blood donors enables selection of antigen nega-
tive platelet products for the treatment of thrombocytopenic patients and patients 
with antiplatelet antibodies. Determination of the maternal, paternal and neonatal 
HPA genotype has a major role for definitive confirmation of FNAITP diagnosis. 
Molecular methods have been increasingly employed for determination of foetal 
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(prenatally) and neonatal HPA genotype from other blood cells, not exclusively 
from platelets, which may frequently be unavailable in the amount necessary for 
serological testing in case of severe thrombocytopenia. Latest researches indicate 
that HPA polymorphism has considerable effect on cell function and can increase 
susceptibility to cerebrovascular and cardiac diseases. The HPA-1b/b phenotype en-
hances the platelet membrane GP IIb/IIIa complex adhesive capacity and increases 
prothrombotic activity. In contrast, the HPA-5a/b polymorphism reduces the risk of 
thrombotic diseases due to functional alterations in the platelet membrane GP Ia/
IIa. Although the HPA 2a/b polymorphism on GP Ib has not been demonstrated to 
be associated with the risk of thrombotic diseases, the antiplatelet autoantibodies 
in ITP patients are known to be more frequently directed against the HPA-2a than 
HPA-2b allotype. Incompatibility in the HPA-3 system is more commonly associa-
ted with the occurrence of acute graft-versus-host disease in HLA-A2 recipients. In 
HPA-5b negative patients, acute vascular graft rejection following allogeneic kidney 
transplantation has been reported. These observations suggest that HPA allotypes 
behave as minor histocompatible antigens [15-18].
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Sažetak
Kliničko značenje antitrombocitnih protutijela
Serološke metode za određivanje antitrombocitnih protutijela pridonijele su razumijevanju 
i boljoj dijagnostici imunološki uzrokovanih trombocitopenija. Iako je većina testova za odre-
đivanje antitrombocitnih protutijela u početku uvedena za dokazivanje protutijela u bolesnika 
s idiopatskom trombocitopenijskom purpurom, danas se ove metode primjenjuju u dijagnostici 
bolesti s poremećajima trombocita, kada se sumnja u imunološki patomehanizam. Serološka se 
ispitivanja. najčešće primjenjuju u dijagnostici fetalne i neonatalne aloimune trombocitopenije 
(FNAITP), poslijetransfuzijske trombocitopenijske purpure (PTP) i refraktornosti na trombocitne 
transfuzije, te primarne i sekundarne autoimune trobocitopenije (ITP). Razvoj molekularne biolo-
gije omogućio je točnije određivanje trombocitnih antigena i proučavanje njihove učestalosti u 
populaciji. Ova saznanja poboljšala su procjenu značenja pojedinih antigenih sustava u nastanku 
auto i aloimunih trombocitopenijskih sindroma, povezanosti HPA polimorfizma sa sklonošću 
srčanim i cerebrovaskularnim bolestima, te ishodu alogenične transplantacije koštane srži i so-
lidnih organa.
Ključne riječi: humani trombocitni antigeni, antitrombocitna auto i aloprotutijela, anti-
HLA-I protutijela, imuna trombocitopenija (ITP), fetalna i neonatalna aloimuna trombocitopeni-
ja (FNATP), poslijetransfuzijska trombocitopenijska purpura (PTP), refraktornost na trombocitne 
transfuzije
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